Merrimack is committed to the fight against cancer. We are a science-driven community seeking to understand the complexity of the disease, engineer better solutions and deliver life-saving results for patients.
We believe the key to achieving a deeper understanding of the complex and dynamic biology behind cancer requires a systems-based understanding of the interactions within a cancer cell and its surrounding environment. Our researchers apply systems biology as a tool to discover and develop better medicines.
Merrimack is using its novel antibody-engineering platform to design therapies targeting critical nodes of the complex signaling pathways that drive many cancers. These approaches consist of developing monoclonal, oligoclonal, bispecific and multispecific antibody based therapies targeting multiple different receptors across various types of cancers.
Merrimack leverages its proprietary nanoliposomal technology to design and develop therapeutics intended to deliver greater concentrations of drug to the tumor site while reducing off-target effects. Through this approach, we believe our nanotechnology platform provides us with the potential to significantly improve the impact of a broad range of therapeutics.
Merrimack is currently using insights gained from our systems biology approach to develop diagnostics designed to help physicians identify which regimens will be best suited for each patient we treat.
Merrimack currently has six therapeutic oncology candidates at different stages of clinical development, multiple product candidates in preclinical development, and an active Network Biology-focused discovery effort.
MM-302 is Merrimack's wholly owned, novel antibody-drug conjugated liposomal doxorubicin that targets and binds to HER2, a protein that when overexpressed can lead to the development and aggressive progression of breast cancer.
Merrimack and Baxalta jointly announced that the New Drug Application (NDA) for MM-398 has been accepted for review by the U.S. Food and Drug Administration (FDA). In addition, the FDA has classified the NDA as having Priority Review status.
Merrimack is seeking U.S. marketing approval of MM-398 for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.
Merrimack is proud to partner with The Pancreatic Cancer Action Network to raise awareness and research efforts for pancreatic cancer. PanCan is the national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure.
The expression of heregulin (HRG), the principal ligand that binds to and activates the ErbB3 receptor, has been found to be associated with poor response to standard of care therapy for patients with platinum-resistant ovarian cancer, ER/PR+ HER2- breast cancer and EGFR wild-type non-small cell lung cancer. Results from three Phase 2 studies indicate that 30-50 percent of patients most at risk of progession may benefit from MM-121, which is designed to block heregulin binding to ErbB3.